Serum catestatin levels and arterial stiffness parameters in patients with Crohn’s disease (CROSBI ID 684044)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Živkovic, Piero Marin ; Tadin Hadjina, Ivana ; Rušic, Doris ; Vilović, Marino ; Borovac, Josip Anđelo ; Šupe Domic, Daniela ; Puljiz, Željko ; Tonkić, Ante ; Božić, Joško ;
engleski
Serum catestatin levels and arterial stiffness parameters in patients with Crohn’s disease
Introduction: Catestatin is endogenous functional protein that acts as an inhibitor of catecholamine secretion. Studies implicate its role in pathophysiology of cardiovascular disorders and various metabolic alterations. Furthermore, recent studies conducted on experimental colitis models suggest upregulation of catestatin in those conditions, and its possible help in attenuating inflammation process. To our best knowledge, there are no published studies that investigated serum catestatin in Crohn’s disease (CD) patients. Therefore, aim of this study was to determine catestatin levels and its connection with arterial stiffness parameters in patients with CD. Methods: This study enrolled 40 patients with diagnosed CD and 40 controls matched in age, gender, and anthropometric measurements. Serum catestatin level was determined with ELISA kit (Phoenix Pharmaceuticals, Phoenix, USA), while arterial stiffness measurement was performed with SphygmoCor device (AtCor Medical, Inc., Sydney, Australia). Results: CD group had significantly greater serum catestatin levels in comparison with controls (10.7 ± 7.8 vs. 6.3 ± 3.4 ng/mL, P=0.004). Additionally, CD patients had higher pulse wave velocity (PWV) (7.6 ± 2.0 vs. 6.3 ± 1.4 m/s, P=0.001) and central augmentation index (Aix) (17.3 ± 14.8 vs. 10.2 ± 12.9%, P=0.026). Furthermore, serum catestatin significantly correlated with PWV (r=0.262, P=0.019) and Aix (r=0.311, P=0.005). Multiple linear regression showed that catestatin remained in significant association with PWV after adjustment for age, sex and BMI (β=0.980, SE=0.4, P=0.019). Finally, multiple logistic regression analysis adjusted for age, sex and BMI revealed that catestatin (OR=1.123, 95% CI=1.013 - 1.243, P=0.026) and PWV (OR=1.706, 95% CI=1.205 - 2.415, P=0.003) were independent and significant predictors of positive CDstatus. Discussion / Conclusion: The results of this study show that patients with CD have higher serum catestatin levels when compared to healthy controls. Furthermore, catestatin may have a role in arterial stiffness in these patients. Further studies are needed to clarify the importance of these findings.
arterial stiffness ; catestatin ; Crohn's disease
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
102
2019.
objavljeno
Podaci o matičnoj publikaciji
IBD: From Pathophysiology to Personalized Medicine - Abstracts
Podaci o skupu
IBD: From Pathophysiology to Personalized Medicine
poster
29.03.2019-30.03.2019
Oxford, Ujedinjeno Kraljevstvo